A Phase I Dose-Escalation Trial of High-Dose Melphalan with Palifermin for Cytoprotection Followed by Autologous Stem Cell Transplantation for Patients with Multiple Myeloma with Normal Renal Function

Biology of Blood and Marrow Transplantation

Volumn 19, Issue 1, 2013, Pages 56-61

  Abidi, Muneer H ^a,c   Agarwal, Rishi ^b   Tageja, Nishant ^d   Ayash, Lois ^a,c   Deol, Abhinav ^a,c   Al Kadhimi, Zaid ^a,c   Abrams, Judith ^a,c   Cronin, Simon ^a   Ventimiglia, Marie ^a   Lum, Lawrence ^a,c   Ratanatharathorn, Voravit ^a,c   Zonder, Jeffrey ^a   Uberti, Joseph ^a,c  

^a KARMANOS CANCER INSTITUTE   (United States)

^b Synergy Medical Education Alliance   (United States)

^c WAYNE STATE UNIVERSITY   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

Author keywords

High dose melphalan; Oral mucositis; Palifermin

Indexed keywords

AMYLASE; MELPHALAN; OPIATE; PALIFERMIN; TRIACYLGLYCEROL LIPASE;

ADULT; AGED; AMYLASE BLOOD LEVEL; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CARDIOTOXICITY; CELL PROTECTION; CLINICAL ARTICLE; CLINICAL EVALUATION; CONTROLLED STUDY; DIARRHEA; DISEASE DURATION; DRUG DOSE ESCALATION; DRUG EFFICACY; EDEMA; FEMALE; HEART ATRIUM FIBRILLATION; HUMAN; INCIDENCE; KIDNEY FUNCTION; MALE; MAXIMUM TOLERATED DOSE; MULTIPLE MYELOMA; ORAL MUCOSITIS; PHASE 1 CLINICAL TRIAL; RASH; SIDE EFFECT; TONGUE DISEASE; TRIACYLGLYCEROL LIPASE BLOOD LEVEL; VOMITING;

ADULT; AGED; CYTOPROTECTION; FEMALE; FIBROBLAST GROWTH FACTOR 7; HUMANS; KIDNEY; MALE; MELPHALAN; MIDDLE AGED; MULTIPLE MYELOMA; MYELOABLATIVE AGONISTS; STEM CELL TRANSPLANTATION; STOMATITIS; TRANSPLANTATION, AUTOLOGOUS;

EID: 84871923086     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2012.08.003     Document Type: Article

References (29)

1. Raab M.S., Podar K., Breitkreutz I., et al. Multiple myeloma. Lancet 2009, 374:324-339.
2. Attal M., Harousseau J.L., Stoppa A.M., et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome. N Engl J Med 1996, 335:91-97.
3. Fermand J.P., Katsahian S., Divine M., et al. High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: long-term results of a randomized control trial from the Group Myelome-Autogreffe. J Clin Oncol 2005, 23:9227-9233.
4. Child J.A., Morgan G.J., Davies F.E., et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003, 348:1875-1883.
5. Bladé J., Rosiñol L., Cibeira M.T., et al. Hematopoietic stem cell transplantation for multiple myeloma beyond 2010. Blood 2010, 115:3655-3663.
6. Samuels B.L., Bitran J.D. High-dose intravenous melphalan: a review. J Clin Oncol 1995, 13:1786-1799.
7. Moreau P., Facon T., Attal M., et al. Comparison of 200 mg/m(2) melphalan and 8 Gy total body irradiation plus 140 mg/m(2) melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergroupe Francophone du Myélome 9502 randomized trial. Blood 2002, 99:731-735.
8. McElwain T.J., Powles R.L. High-dose intravenous melphalan for plasma-cell leukaemia and myeloma. Lancet 1983, 2:822-824.
9. Moreau P., Milpied N., Mahé B., et al. Melphalan 220 mg/m2 followed by peripheral blood stem cell transplantation in 27 patients with advanced multiple myeloma. Bone Marrow Transplant 1999, 23:1003-1006.
10. Hollmig K, Stover J, Talamo G, et al. Addition of bortezomib (Velcade) to high dose melphalan (Vel-Mel) as an effective conditioning regimen with autologous stem cell support in multiple myeloma (MM). The American Society of Hematology 46th Annual Meeting and Exposition, December 4-7, 2004, San Diego, California. Abstract 929.
11. Barlogie B., Jagannath S., Desikan K.R., et al. Total therapy with tandem transplants for newly diagnosed multiple myeloma. Blood 1999, 93:55-65.
12. Moreau P., Hullin C., Garban F., et al. Tandem autologous stem cell transplantation in high-risk de novo multiple myeloma: final results of the prospective and randomized IFM 99-04 protocol. Blood 2006, 107:397-403.
13. Spencer A., Horvath N., Gibson J., et al. Prospective randomised trial of amifostine cytoprotection in myeloma patients undergoing high-dose melphalan conditioned autologous stem cell transplantation. Bone Marrow Transplant 2005, 35:971-977.
14. Capelli D., Santini G., De Souza C., et al. Amifostine can reduce mucosal damage after high-dose melphalan conditioning for peripheral blood progenitor cell autotransplant: a retrospective study. Br J Haematol 2000, 110:300-307.
15. Thieblemont C., Dumontet C., Saad H., et al. Amifostine reduces mucosal damage after high-dose melphalan conditioning and autologous peripheral blood progenitor cell transplantation for patients with multiple myeloma. Bone Marrow Transplant 2002, 30:769-775.
16. Rubenstein E.B., Peterson D.E., Schubert M., et al. Clinical practice guidelines for the prevention and treatment of cancer therapy-induced oral and gastrointestinal mucositis. Cancer 2004, 100:2026-2046.
17. Lilleby K., Garcia P., Gooley T., et al. A prospective, randomized study of cryotherapy during administration of high-dose melphalan to decrease the severity and duration of oral mucositis in patients with multiple myeloma undergoing autologous peripheral blood stem cell transplantation. Bone Marrow Transplant 2006, 37:1031-1035.
18. Rubin J.S., Osada H., Finch P.W., et al. Purification and characterization of a newly identified growth factor specific for epithelial cells. Proc Natl Acad Sci U S A 1989, 86:802-806.
19. Blijlevens N., Sonis S. Palifermin (recombinant keratinocyte growth factor-1): a pleiotropic growth factor with multiple biological activities in preventing chemotherapy- and radiotherapy-induced mucositis. Ann Oncol 2007, 18:817-826.
20. Meropol N.J., Somer R.A., Gutheil J., et al. Randomized phase I trial of recombinant human keratinocyte growth factor plus chemotherapy: potential role as mucosal protectant. J Clin Oncol 2003, 21:1452-1458.
21. Spielberger R., Stiff P., Bensinger W., et al. Palifermin for oral mucositis after intensive therapy for hematologic cancers. N Engl J Med 2004, 351:2590-2598.
22. Kobbe G., Bruns I., Schroeder T., et al. A 3-day short course of palifermin before HDT reduces toxicity and need for supportive care after autologous blood stem-cell transplantation in patients with multiple myeloma. Ann Oncol 2010, 21:1898-1904.
23. Abidi M.H., Agarwal R., Ayash L., et al. Melphalan 180 mg/m2 can be safely administered as conditioning regimen before an autologous stem cell transplantation (ASCT) in multiple myeloma patients with creatinine clearance 60 mL/min/1.73 m(2) or lower with use of palifermin for cytoprotection: results of a Phase I trial. Biology Blood Marrow Transplant 2012, 18:1455-1461.
24. NCI Common Toxicity Criteria version 3.0. Available at: Accessed: June 21, 2012. http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm#ctc_30.
25. Blijlevens N.M., Donnelly J.P., De Pauw B.E. Mucosal barrier injury: biology, pathology, clinical counterparts and consequences of intensive treatment for haematological malignancy: an overview. Bone Marrow Transplant 2000, 25:1269-1278.
26. Ruescher T.J., Sodeifi A., Scrivani S.J., et al. The impact of mucositis on alpha-hemolytic streptococcal infection in patients undergoing autologous bone marrow transplantation for hematologic malignancies. Cancer 1998, 82:2275-2281.
27. Lark R.L., McNeil S.A., VanderHyde K., et al. Risk factors for anaerobic bloodstream infections in bone marrow transplant recipients. Clin Infect Dis 2001, 33:338-343.
28. Grazziutti M.L., Dong L., Miceli M.H., et al. Oral mucositis in myeloma patients undergoing melphalan-based autologous stem cell transplantation: incidence, risk factors and a severity predictive model. Bone Marrow Transplant 2006, 38:501-506.
29. Pierce G., Yanagihara D., Klopchin K., et al. Stimulation of all epithelial elements during skin regeneration by keratinocyte growth factor. J Exp Med 1994, 179:831-840.